Masimo SpHb® noninvasional continuous hemoglobin monitoring as part of blood management in children can reduce ICU retention time and postoperative blood transfusions

Masino (NASDAQ: MASI) recently released the results of a summary of the latest report in Euroanaesthesia 2020: Dr. Saraçoğlu of the University of Marmara in Istanbul, Turkey, and colleagues investigated the effectiveness of Massimo's noninvasive continuous hemoglobin monitoring SpHb® as a component of blood transfusion management in children undergoing major surgery1.
The researchers noted that traditional hemoglobin measurement and blood loss estimation methods are "time-consuming" and can lead to delays in decision-making as part of perioperative blood transfusion management, and sought to investigate whether the use of Massimo SpHb noninvasive continuity affected blood transfusion rates, disease rates, and mortality rates in children receiving premature fusion therapies of the skull seams.
divided the 2-24 month-old children into two groups, the control group (n - 28 cases) using intermittent blood gas analysis for blood transfusion therapy management, the experimental group (n - 27 cases) using SpHb for blood transfusion therapy management, with the connection to Radical-7® pulse oxygen-oxygen saturation meter ® Masimo Rainbow ® sensor.
both groups were blood gas analysis during peri-surgery, once an hour, and in the SpHb group, blood gas analysis was carried out simultaneously when SpHb monitoring showed a sudden drop in hemoglobin.
the researchers calculated that the following results were statistically significant (p 0.05): Transfer to control group SpHb group P value ICU retention time 55.43 hours ± 25.34 hours (medium 48 hours) 33.48 hours ± 12.25 hours (medium 24 hours) 0.001 postoperative drain 215.54 ml ± 93.1 ml 136.85 ml ± 62.27 ml 0.001 ml postoperative red blood cell transfusion 179.02 ml ± 163.06ml (145ml) 102.69ml ± 73.87ml (105ml) 0.033ml fresh freeze-dried plasma transfusion 71.96ml ± 94.95ml (25) ml) 28.15 ml ± 64.35 ml (0 ml) 0.043 ternate crystal rehydration 396.79 ml ± 171.16 ml (350 ml) 462.59 ml ± 158.91 ml (500 ml) 0.048 ICU first plate level 270,821 ± 74,474327,185 ± 104,6440.025 ICU final lactic acid level 1.47 Millimolar/L ± 0.64 mmol/L (1.25 mmol/L) 1.18 mmol/L ± 0.63 mMol/L (0.9 mmol/L) 0.044 they found that the control group ICU retention time was significantly longer than in the SpHb group.
control group ICU after surgery drain, red blood transfusion, fresh freeze-dried plasma transfusion was also higher than spHb group, the difference is statistically significant.
, the SpHb group had higher lactic acid levels, but at the end of the operation, the control group was higher.
researchers concluded: "Noninvasive continuous hemoglobin monitoring during haemorrhage surgery in children not only reduces blood transfusions, but also reduces metabolic and hemodynamic instability, thereby effectively reducing the rate of disease loss."
" other adult patient clinical studies have found that continuous monitoring of SpHb as part of the Patient Blood Management (PBM) program can improve re-transfer, such as reducing the percentage of patients receiving blood transfusions2, reducing the number of red blood cell transfusions per patient by 3-4, reducing the time to blood transfusion 5, reducing spending 6 days, and even 30 days after surgery and 90 days of mortality by 33% and 29% 7, respectively.
spHb effects are found around the world, from 6 countries on four continents 2-8.
today, SpHb technology supports clinicians in more than 75 countries around the world9.
SpHb is not intended to replace laboratory blood testing.
clinical decisions about red blood cell transfusions must be based on the clinical community's judgment of the following factors: patient condition, continuous SpHb monitoring and laboratory diagnostic testing using blood samples, etc.
@Masimo ( #MasimoMasimoMasimo NASDAQ: MASI) is a global medical technology company that develops and produces a wide range of industry-leading monitoring technologies, including innovative measurement equipment, sensors, patient monitors, automation and interoperability solutions.
our mission is to improve patient referral and reduce treatment costs.
1995, the company introduced the Massimo SET® Mobile and Low Perfusion Measurement (Measure-through Motion and Low Perfusion™) pulse oxygen saturation meter, which more than 100 independent objective studies have shown to perform better than other pulse oxygen saturation meter technologies10.
studies have shown that Masimo SET® can help clinicians reduce severe retinal lesions in premature newborns11, improve CCHD screening in newborns12, and reduce rapid response team mobilization, ICU transport, and cost 13-16 when continuous monitoring of Massimo Patient SafetyNet™ for postoperative wards.
Masimo SET® is estimated to have been used in more than 200 million patients in the world's leading hospitals and other medical institutions17, and is the main pulse oxygen saturation meter used by 9 of the top 10 hospitals in U.S. News and World Report's 2020-21 Best Hospital Honors List18.
Masimo continuously optimizes SET®, announcing in 2018 that spo2 accuracy on RD SET® sensors in mobile states has been significantly improved, convinced clinicians that the SpO2 values they rely on accurately reflect the patient's physiological state.
2005, Masimo introduced the rainbow® pulse carbon-oxygen saturation meter technology, enabling noninvasive continuous monitoring of blood content that was previously only invasively measured, including total hemoglobin (SpHb®) and oxygen content (SpOC™ ), carbon hemoglobin (SpCO®), high iron hemoglobin (SpMet®), pulse perfusion variation index (PVi®), RPVi™ (rainbow® PVi), oxygen reserve index (ORi™).
2013, Masimo launched the Root® Patient Monitoring and Interoperability Platform, which is designed from scratch to be as flexible and scalable as possible to add additional Masimo and third-party monitoring technologies.
key Masimo additions include the next-generation SedLine® brain function monitor, the O3® local oxygen saturation meter, and the ISA™22 analyzer with NomoLine®s sampling cable.
Massimo's continuous and point monitor pulse carbon-oxygen saturation meter ® family includes devices designed for a wide range of clinical and non-clinical applications, including wireless wearable technologies such as Radius-7® and Radius PPG™), portable devices (e.g. Rad-67™), fingertip pulse oxygen saturation meters (e.g. MightySat®Rx), hospital and home-based devices (e.g. Rad-97®).
Masimo's in-house automation and interoperability solutions are centered on the Massimo Hospital Automation™ platform, which includes Iris Gateway®, Patient SafetyNet, Replica ™, Halo ION™, UniView™, UniView: 60™, Masimo SafetyNet™
for further information about Masimo and its products, please visit .
have published clinical studies on Masimo products, please visit .
ORi and RPVi were not approved by FDA 510(k) and were not listed in the United States.
The Patient SafetyNet trademark is licensed for use by United Health System Consortium.
references Saraçoğlu A, Orhon Ergün M, Sakar M, Uyar E, Saçak B, Ayka? Z. The use of SpHb in pediatrics, the reving major surgery with a reduced morbidity. Proceedings from the Euroanaesthesia 2020 Annual Meeting. #5291.(Saraçoğlu A、Orhon Ergün M、Sakar M、Uyar E、Saçak B、Aykaç Z。
children undergoing major surgery can reduce the rate of disease loss.
a collection of Papers from Euroanaesthesia 2020.
number 5291.
)Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring during Orthopedic Surgery: A Randomized Trial. J Blood Disorders Transf. 2014. 5:9. 2. (Ehrenfeld JM et al.
hemoglobin monitoring during orthopaedic surgery: randomized trials.
Journal of Blood Diseases and Blood Transfusions 2014. 5:9. 2)Awada WN et al. Continuous and noninvasive hemoglobin monitoring reduces red blood cell transfusion during neurosurgery: a prospective cohort study. J Clin Monit Comput. 2015 Feb 4. (Awada WN, etc.).
continuous noninvasive hemoglobin monitoring can reduce red blood cell transfusions during neurosurgery: prospective cohort study.
Journal of Clinical Monitoring and Computing, February 4, 2015.
)Imaizumi et al. Continuous and noninvasive hemoglobin monitoring may reduce excessive intraoperative RBC transfusion. Proceedings from the 16th World Congress of Anaesthesiologists, Hong Kong. Abstract #PR607. (Imaizumi, etc.).
continuous noninvasional hemoglobin monitoring can reduce excessive blood transfusion of red blood cells in surgery.
abstract of the 16th World Congress of Anesthesiologists in Hong Kong.
)Kamal AM et al. The Value of Continuous Noninvasive Hemoglobin Monitoring in Intraoperative Blood Transfusion Practice During Abdominal Cancer Surgery. Open J Anesth. 2016; 13-19. (Kamal AM, etc.).
value of continuous noninvasional hemoglobin monitoring in blood transfusion practice during abdominal cancer surgery.
Journal of Anesthesiology 6, 13-19) Ribed-Sánchez B et al. Economic Analysis of the Reduction of Blood Transfusions during Surgical Procedures While Continuous Hemoglobin Monitoring is Used. Sensors. 2018, 18, 1367; doi:10.3390/s18051367. (Ribed-Sánchez B, etc.).
analysis of reducing blood transfusions using continuous hemoglobin monitoring during surgery.
Sensor 2018, 18, 1367; doi:10.3390/s18051367)Cros J et al. Continuous hemoglobin and plethysmography variability index monitoring can modify blood transfusion practice and is associated with lower mortality. J Clin Monit Comp. 3 Aug 2019.(Cros J, etc.).
continuous hemoglobin and pulse perfusion variation index monitoring can improve blood transfusion practice and reduce mortality.
Journal of Clinical Monitoring and Computing, August 3, 2019.
)Merolle L et al. Postoperative patient blood management: transfusion appropriateness in cancer patients. Blood Tra。